Both the capitalized research and development costs as well as the average cost of investments were higher than previous estimates from other researchers.
The issue of rising drug costs has been front and center in the United States, influencing political and policy debates, raising concerns about patient access, and stirring questions about the level of biopharmaceutical prices and profit required to recoup investment in new therapies.
In an effort to quantify how much drug companies spend to bring a new drug to market, a study published in JAMA Tuesday found that, inclusive of the cost of failed trials, research and development (R&D) costs were $985 million, and that the mean investment was $1.4 billion.
Between 2009 and 2018, the FDA approved 355 new drugs; this study analyzed 63 of those. Of the 63, 16, or 25%, were biologics.
Using publicly available data, researchers found $985.3 million (95% CI, $683.6 million-$1228.9 million) in R&D costs, and said the mean investment was estimated at $1335.9 million (95% CI, $1042.5 million-$1637.5 million) in the base case analysis.
Authors examined R&D estimates by therapeutic areas with 5 or more drugs (oncology, metabolism and endocrinology, cardiovascular, central nervous system, autoimmune and inflammation, opthamology, and infectious disease).
Median estimates ranged from $765.9 million (95% CI, $323.0 million-$1473.5 million) for nervous system agents to $2771.6 million (95% CI, $2051.8 million-$5366.2 million) for antineoplastic and immunomodulating agents.
Both the capitalized R&D costs as well as the average cost of investments were higher than previous estimates from other researchers. Other recent estimates had ranged from $314 million to $2.8 billion; the authors said the differences may stem from the types of data used (ie, public vs private) as well as the range of drug products analyzed.
Researchers stressed the importance for policy makers, regulators, and payers to know the exact scale of investments in development. “This knowledge can inform the design of pricing policies that give adequate rewards for innovative drugs that bring value to health care systems,” they wrote.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15th 2024Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.